Clinical Trial Update: Erlotinib Plus Bevacizumab in Hepatocellular Carcinoma (HCC) as Second-line Therapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating erlotinib plus bevacizumab as second-line therapy for hepatocellular carcinoma has completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma
• Liver Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• ERLOTINIB (Erlotinib)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Liver Cancer | Phase 2 | Status: COMPLETED | Results posted: 2022-11-07